Intuitive Surgical's growth case now rests on a class of procedure where its record is weakest. The company built a near-monopoly by displacing open surgery in the deep pelvis. The volume still left to win sits mostly in benign, high-throughput operations. There, the comparison is laparoscopy, which is cheap and good enough. The headline figures argue against this read: roughly $12 billion of revenue this year, 84% of it recurring, a non-GAAP operating margin near 40%, more than 10,000 procedures a day on over 12,000 installed systems. But those numbers describe a toll that has already been built. The decision variable for the next leg is whether surgeons and hospitals will pay that toll on a gallbladder.
The irony sits at the very start of the company's history. In March 1997, Jacques Himpens and Guy-Bernard Cadière used a prototype the engineers called "Mona" to remove a gallbladder from a console a few feet from the patient. That was the first robot-assisted operation on a human, and it was a cholecystectomy. Nearly three decades later, cholecystectomy is again the procedure at the center of the debate.
Open Surgery Was the Real Competitor
Intuitive's own planning got the source of its success wrong. That fact matters more than any market-size slide. The 2000 prospectus named gallbladder, hernia, hysterectomy and cardiac as target procedures. It never mentioned the prostate. Yet prostatectomy became the defining adoption story. Urologists took da Vinci from near zero to more than 80% of US prostatectomies within about a decade, faster than any procedure before or since, and gynecology followed.
The mechanism behind that adoption explains why the playbook does not transfer cleanly. The robot's decisive advantage was not dexterity over laparoscopy. It was less trauma than open surgery. Laparoscopy uses long, rigid instruments through small incisions. Those instruments struggle deep in the pelvis, so prostatectomies were still largely done open. The robot did not beat keyhole surgery in that setting. It made keyhole-style surgery possible where it had barely existed. Hospitals were paying to replace a large incision, and the clinical gap justified the price.
A gallbladder is a different case. Laparoscopic cholecystectomy is routine, fast and inexpensive. When the robot competes against a laparoscopic standard, the clinical gap narrows and the economic question takes over.
The 2013 Hysterectomy Shock as a Template
This is not hypothetical. The company has already lived through it once. In February 2013, a JAMA study of 264,000 hysterectomies found robotic cases cost $2,189 more than laparoscopic ones, with no difference in complications. In March, the president of the American College of Obstetricians and Gynecologists told patients to "separate the marketing hype from the reality." In July, the FDA issued a warning letter over adverse-event reporting. Benign gynecology growth stalled, system sales fell, and investors began asking whether the robot was worth its price.
The lesson of that year is narrow and specific. The robot's value proposition came under pressure at exactly the point where the comparator shifted from open surgery to laparoscopy. Benign hysterectomy was the first large, cost-sensitive, laparoscopy-competitive category Intuitive pushed into at scale, and that is where outcome data and professional bodies pushed back. Cholecystectomy, hernia and similar general surgery procedures share the same profile: benign, high volume, already well served by keyhole technique.
This is a pattern worth watching rather than a rule. Device history includes technologies that won on workflow, consistency or surgeon ergonomics even without a measurable outcome edge. Intuitive's own recovery after 2013 is partial evidence of that.
Recurring Revenue Turns Adoption Into a Per-Case Bet
The 84% recurring share is usually read as a sign of quality, and it is one. It also changes what the growth debate is about. When most revenue arrives through instruments, accessories and service tied to use, each new procedure category matters through the revenue it generates per case and the frequency of use. Placing more systems matters less. A system installed for general surgery earns its keep only if it runs high-volume cases. High-volume cases are exactly the ones where hospitals feel the per-case premium most.
That creates a tension the headline margin hides. A roughly 40% non-GAAP operating margin reflects pricing power built in procedures where the robot had little real competition. Expanding into laparoscopy-competitive categories can push in two directions. Intuitive can defend per-case pricing and accept slower penetration. Or it can concede on economics to win volume, which would show up first in recurring revenue per procedure rather than in total revenue. Total revenue can keep compounding while the economics of each new procedure worsen.
The lens here is disclosure, not narrative. The margin figure cited for this year is non-GAAP. For a company that compensates heavily in stock, the distance between adjusted and reported operating margin is the first reconciliation an investor should read in the filings. The same applies to any TAM framing. Intuitive describes its opportunity as "23 Million, 20 Million, 9 Million" procedure pools. The full mapping of those figures sits behind the source's paywall and is not reproduced here. The relevant test is how much of each pool is open surgery, which the robot wins on trauma, and how much is already laparoscopic, which it must win on cost.
Why the Moat Held Last Time
The strongest objection to this thesis is the company's own track record of surviving exactly this kind of worry. That record deserves full weight.
After 2013, management did not cut prices into weakness. It kept shipping. The fourth-generation da Vinci Xi in 2014 reopened multi-quadrant general surgery. The single-port SP followed in 2018, and Ion, a robotic bronchoscope for lung biopsy, in 2019. In 2016, investors feared a patent cliff as the original patents expired and about a dozen challengers announced robots. A decade later, most of those challengers are gone. The pandemic cut procedure growth to 1% in 2020, and growth came roaring back.
The patent episode is the more telling one. Intuitive's early dominance had a legal basis. In August 2002, a Delaware jury found that Computer Motion's AESOP and ZEUS infringed a patent Intuitive had licensed from IBM. Three months later the two cash-burning rivals agreed to merge, which consolidated the foundational surgical robotics patents inside one company. First full-year profit came in 2004. When those patents aged out, the moat did not go with them. Whatever protects Intuitive today is something other than intellectual property, likely the installed base, surgeon training pipelines and hospital workflow built around the platform. That attribution is inference: the source does not break the moat down, and its competitive section is paywalled. It is still the most consistent explanation for a dozen funded entrants failing against a technology that was legally open to copy.
The long-run return reflects this. The 2000 IPO was cut from 8 million shares at $11 to $13 down to 5 million at $9, after the Nasdaq peak and Computer Motion's lawsuit landed at the same moment. On a split-adjusted basis that is about $2 a share. At $452, it works out to roughly 23% a year compounded over 26 years. A company that recovered from an IPO cut, a patent war, a JAMA study, an FDA warning letter and a feared patent cliff has earned some benefit of the doubt.
What that record does not show is a win in a laparoscopy-dominated benign category on clear economic terms. The post-2013 recovery came through new platforms and new procedure types, not through the hospital cost debate in benign hysterectomy being settled in the robot's favor. The moat explains why competitors failed. It does not explain why a hospital should pay a premium for a gallbladder.
Leadership Continuity and the Return Hurdle
Dave Rosa took over as CEO in July 2025. He is only the third chief executive in the company's history, after Lonnie Smith (1997 to 2009) and Gary Guthart (2010 onward). Rosa and Guthart were both early engineering hires in 1996; Rosa joined in March of that year as the ninth employee. That continuity is unusual and mostly an asset. It also means the company's strategic instinct has been shaped by the playbook that worked: answer skepticism with new product rather than new pricing.
At $452, the forward return no longer depends on proving the robot works. That question was answered years ago. It depends on procedure volume in categories where the robot's advantage is ergonomic and operational rather than clinical. A ~10% annual return from here needs that volume growth at economics close to today's. If benign general surgery requires lower pricing per case, total revenue can keep rising while the margin structure that justifies the multiple erodes slowly. The 23% compounding history included multiple expansion from a speculative IPO base, and that tailwind does not repeat from a dominant, highly profitable incumbent.
The Condition That Decides It
The observable test is recurring revenue per procedure as general surgery becomes a larger share of the mix. If that figure holds roughly steady while cholecystectomy, hernia and other benign general cases grow, then hospitals are paying for something beyond the clinical outcome, whether throughput, consistency or surgeon retention. In that case the 2013 lesson was specific to gynecology. If per-procedure revenue drifts lower as the mix shifts, or if a large outcomes study does for general surgery what the 2013 JAMA paper did for hysterectomy, the company will face the same cost question in its largest remaining pool. The first robotic operation was a gallbladder, and the next decade's returns depend on gallbladder economics.
